FOSUN PHARMA's Cisplatin Injection Marketing Application Accepted for Review

Stock News

Feb 13

FOSUN PHARMA (02196) announced that the marketing authorization application for Cisplatin Injection, submitted by its controlling subsidiary, Gismee (Wuhan) Pharmaceutical Co., Ltd., has been accepted by the National Medical Products Administration. This chemical drug, developed independently by the group, is intended for the treatment of metastatic testicular tumors, metastatic ovarian tumors, and advanced bladder cancer. As of January 2026, the group's cumulative R&D investment for this drug amounts to approximately RMB 4.69 million (unaudited). According to the latest data from IQVIA CHPA, the sales of Cisplatin Injection in mainland China (excluding Hong Kong, Macao, and Taiwan regions) reached approximately RMB 165 million in 2024.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1192481164"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1192481164\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1192481164?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-13 17:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1192481164","market":"hk","top_or_hot":-1,"title":"FOSUN PHARMA's Cisplatin Injection Marketing Application Accepted for Review","media":"Stock News","content":"<p>FOSUN PHARMA (02196) announced that the marketing authorization application for Cisplatin Injection, submitted by its controlling subsidiary, Gismee (Wuhan) Pharmaceutical Co., Ltd., has been accepted by the National Medical Products Administration. This chemical drug, developed independently by the group, is intended for the treatment of metastatic testicular tumors, metastatic ovarian tumors, and advanced bladder cancer. As of January 2026, the group's cumulative R&D investment for this drug amounts to approximately RMB 4.69 million (unaudited). According to the latest data from IQVIA CHPA, the sales of Cisplatin Injection in mainland China (excluding Hong Kong, Macao, and Taiwan regions) reached approximately RMB 165 million in 2024.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FOSUN PHARMA's Cisplatin Injection Marketing Application Accepted for Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFOSUN PHARMA's Cisplatin Injection Marketing Application Accepted for Review\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-02-13 17:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>FOSUN PHARMA (02196) announced that the marketing authorization application for Cisplatin Injection, submitted by its controlling subsidiary, Gismee (Wuhan) Pharmaceutical Co., Ltd., has been accepted by the National Medical Products Administration. This chemical drug, developed independently by the group, is intended for the treatment of metastatic testicular tumors, metastatic ovarian tumors, and advanced bladder cancer. As of January 2026, the group's cumulative R&D investment for this drug amounts to approximately RMB 4.69 million (unaudited). According to the latest data from IQVIA CHPA, the sales of Cisplatin Injection in mainland China (excluding Hong Kong, Macao, and Taiwan regions) reached approximately RMB 165 million in 2024.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0188","symbol_name":"融资融券","start_time":0,"source_url":"","article_id":"1192481164","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1192481164","pubTimestamp":1770976456,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"FOSUN PHARMA (02196) announced that the marketing authorization application for Cisplatin Injection, submitted by its controlling subsidiary, Gismee (Wuhan) Pharmaceutical Co., Ltd., has been...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK0188":"融资融券","BK1191":"制药","BK1515":"抗疫概念","BK0096":"民营医院","BK1593":"医美概念股","02196":"复星医药","BK0012":"证金概念","BK0196":"行业龙头","BK0175":"白马股","BK0060":"抗癌","BK0187":"一线龙头","BK0028":"国家队","BK0239":"医药制造","BK0183":"MSCI概念"},"translate_title":"复星医药顺铂注射液上市申请获审评受理","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1,"02196":1},"content_text":"FOSUN PHARMA (02196) announced that the marketing authorization application for Cisplatin Injection, submitted by its controlling subsidiary, Gismee (Wuhan) Pharmaceutical Co., Ltd., has been accepted by the National Medical Products Administration. This chemical drug, developed independently by the group, is intended for the treatment of metastatic testicular tumors, metastatic ovarian tumors, and advanced bladder cancer. As of January 2026, the group's cumulative R&D investment for this drug amounts to approximately RMB 4.69 million (unaudited). According to the latest data from IQVIA CHPA, the sales of Cisplatin Injection in mainland China (excluding Hong Kong, Macao, and Taiwan regions) reached approximately RMB 165 million in 2024.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}